date:Sep 28, 2012
ific opinion on a health claim related to its Femilub supplement for the maintenance of vaginal moisture.
However EFSA's NDA panel rejected both claims, stating that Vivatechs Transitech had not been sufficiently characterised in the dossier, and that Nutrilinks had provided no human intervention studies for its food supplement Femilub.
No human intervention studies were provided from which conclusions could be drawn for the scientific substantiation of the claim, said EFSA. A cause and effec